Product Reports Resources Pricing Login Book a demo

Caris Life Sciences

Biotech & Life Sciences · Irving, United States · Founded 1996 · IPO 2025

Caris Life Sciences is a pioneering company that operates at the intersection of molecular science and artificial intelligence, with a primary focus on revolutionizing cancer care. The company provides comprehensive molecular information to cancer patients and oncologists, aiding in the development of personalized treatment plans. This is achieved by understanding the molecular features of a cancer when the diagnosis is made, which can provide insights into how the cancer may behave and what treatments may be most effective. Caris Life Sciences' business model is centered on providing high-quality, reliable molecular information to help improve the lives of as many people as possible. The company's clients are primarily oncologists and cancer patients, but also include researchers and payors in the healthcare sector. The company generates revenue by offering its transformative technologies and services to these clients, thereby helping them navigate, advance, and reinvent cancer care. The company is committed to quality and innovation, and this is reflected in its hiring practices. Caris Life Sciences seeks to employ the brightest minds in scientific, medical, and professional fields to help fulfill the promise of personalized medicine. The company's dedication to its mission is evident in the opportunities it provides to its employees, as well as in the positive experiences shared by team members. In summary, Caris Life Sciences is a leading innovator in molecular science, using artificial intelligence to revolutionize cancer care by providing comprehensive molecular information to patients, oncologists, researchers, and payors. Keywords: Molecular Science, Artificial Intelligence, Cancer Care, Personalized Treatment, Oncologists, Cancer Patients, Healthcare Sector, Transformative Technologies, Quality Commitment, Personalized Medicine.

Valuation $4.03B
Revenue $1.00B
EBITDA $153M
Total funding $1–2.5B

Investors

23 investors on Caris Life Sciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 23 investors entered at this stage
Sixth Street Growth
Coatue Management
Neuberger Berman
Millennium Management
First Light Asset Management
OrbiMed
Highland Capital Management
ClearBridge Investments
T. Rowe Price
Silver Lake Partners
Fidelity Investments
Pura Vida Investments
CPP Investments
Columbia Threadneedle Investments
Tudor Group
Rock Springs Capital
Eaton Vance Management
Braidwell
Woodline Partners
Perceptive Advisors
Ghisallo Partners
Blackstone
Blue Owl Capital

Global footprint

Where Caris Life Sciences has talent and traffic

Workforce by country
8 countries with
team presence
🇺🇸 United States98.6%
🇨🇭 Switzerland0.3%
🇯🇵 Japan0.2%
🇲🇾 Malaysia0.1%
🇵🇪 Peru0.1%
Top 5 of 8 shown
Web traffic by country
41K monthly visits
across markets
🇺🇸 United States59%
🇦🇺 Australia7.1%
🇨🇦 Canada6.1%
🇮🇳 India5.4%
🇬🇧 United Kingdom4.6%
Top 5 markets shown

Talent graph

The shape of Caris Life Sciences's talent

Dealroom maps Caris Life Sciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 standout operatorsDealroom-flagged across the org
27 AI specialistsincl. 6 core researchers
1,694 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Caris Life Sciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$40M patent portfolio · 23 active families

Estimated portfolio value
$40M
1.00% of market cap · 13.7× larger than top peer Owkin ($3M)
23 active patent families
Where Caris Life Sciences innovates Biologic markerBiological organismDiseaseMolecular biologyAptamer

Where Caris Life Sciences concentrates vs peers

Each axis is a top-10 topic across Caris Life Sciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Caris Life Sciences

An AI-synthesized read of the highest-engagement posts about Caris Life Sciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Caris Life Sciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.